The company reported its second late-stage study success, this time with a drug that could become a new treatment standard ...
BridgeBio's encaleret trial for autosomal dominant hypocalcemia type 1 met all goals, showing superior results. Read more ...
The CALIBRATE study of encaleret for patients with ADH1 met all pre-specified primary and key secondary efficacy endpoints - ...
The search for a treatment for limb-girdle muscular dystrophy was started by the family of former Bank of America Corp. CEO ...
BridgeBio Pharma Inc.’s drug to treat a devastating muscle-wasting disorder met its goal in a late-stage trial, paving the ...
BridgeBio Pharma shares surge on positive BBP-418 trial results for limb-girdle muscular dystrophy. Read more here.
BridgeBio Pharma is having a banner week, with the Bay Area company’s encaleret acing a phase 3 trial just days after another ...
BBP-418 hit the mark in the phase 3 FORTIFY trial by achieving a significant increase in glycosylated alpha-dystroglycan (αDG ...
Analysts estimate that BridgeBio Pharma will report an earnings per share (EPS) of $-0.82. The announcement from BridgeBio ...
Already sky high after the success of its limb-girdle muscular dystrophy therapy, reported on Monday, BridgeBio’s shares rose nearly 8% more as encaleret balanced calcium levels in patients with a ...
Investor's Business Daily on MSN
BridgeBio Pharma Lines Up Another 'Domino' As It Nears A Record High
A second positive "domino" fell for BridgeBio stock on Wednesday after the company reported promising results for a genetic ...
The biotech’s phase 3 delivered the hoped-for second biomarker hit, reporting an 82% decline in serum creatine kinase after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback